Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

In Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

Marking a new step forward in its international growth, Spanish privately-held pharma company Esteve has entered into an ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Transcend Capital Advisors LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 30.7% during the 1st quarter, according to its most recent 13F filing with the Securities and ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...